The Royal Free Hospital - Royal Free London NHS Foundation Trust
Welcome,         Profile    Billing    Logout  
 1 Trial 
29 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chinoy, Hector
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
MYOJAK, NCT04208464 / 2019-003868-42: JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM

Completed
2a
15
Europe
Baricitinib
University of Manchester, Eli Lilly and Company, Clinical Trials Unit, Manchester, Karolinska Institutet
Idiopathic Inflammatory Myopathies
09/23
09/23
MYOPROSP, NCT02468895: - a Prospective Cohort Study in Myositis

Active, not recruiting
N/A
300
Europe
University of Manchester, University of Bath, University College, London, Royal Victoria Infirmary, King's College Hospital NHS Trust, North Bristol NHS Trust, University of Liverpool, St. George's Hospital, London, Northern Care Alliance NHS Foundation Trust, Burton Hospitals NHS Foundation Trust, Doncaster And Bassetlaw Hospitals NHS Foundation Trust, Sandwell & West Birmingham Hospitals NHS Trust, London North West Healthcare NHS Trust, Nottingham University Hospitals NHS Trust, Sheffield Teaching Hospitals NHS Foundation Trust
Myositis, Idiopathic Inflammatory Myopathy
12/30
12/30
Ong, Voon
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
NCT05650567: Study of M5049 in DM and PM Participants (NEPTUNIA)

Recruiting
2
40
Europe, US, RoW
M5049 high dose, Enpatoran, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Dermatomyositis, Polymyositis
04/25
04/25
Kallen, John Dominic Van der
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
Coppieters, Sabine
ADDRESS, NCT04598451 / 2020-002915-23: A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

Completed
3
222
Europe, Japan, US, RoW
efgartigimod PH20 SC, Placebo, prednisone
argenx
Pemphigus Vulgaris, Pemphigus Foliaceus
08/23
08/23
ADAPT NXT, NCT04980495 / 2021-002504-12: An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis

Active, not recruiting
3
69
Europe, Canada, US, RoW
Efgartigimod concentrate for solution for infusion 20 mg/mL, Efgartigimod IV
argenx
Generalized Myasthenia Gravis
08/23
05/26
ADVANCE SC, NCT04687072 / 2020-004032-21: A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

Completed
3
207
Europe, Japan, US, RoW
Efgartigimod PH20 SC, ARGX-113 PH20 SC, Placebo PH20 SC
argenx, argenx BV
Primary Immune Thrombocytopenia
10/23
10/23
NCT06298552: A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

Recruiting
3
110
Europe, Canada, US, RoW
Efgartigimod IV, Placebo IV
argenx
Generalized Myasthenia Gravis
07/25
07/27
ADDRESS+, NCT04598477 / 2020-002917-16: A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

Terminated
3
183
Europe, Japan, US, RoW
efgartigimod PH20 SC, prednisone
argenx
Pemphigus Vulgaris, Pemphigus Foliaceus
03/24
03/24
BALLAD+, NCT05681481 / 2021-003063-10: A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants with Bullous Pemphigoid

Active, not recruiting
3
160
Europe, Japan, US, RoW
efgartigimod PH20 SC, Prednisone
argenx, argenx BV
Bullous Pemphigoid
01/26
03/26
ADVANCE SC+, NCT04812925 / 2020-004033-20: A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients with Primary Immune Thrombocytopenia

Active, not recruiting
3
173
Europe, Japan, US, RoW
efgartigimod PH20 SC, ARGX-113 PH20 SC
argenx
Primary Immune Thrombocytopenia
10/26
10/26
ALKIVIA+, NCT05979441: A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy

Enrolling by invitation
3
240
Europe, US, RoW
EFG PH20 SC
argenx
Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
09/27
09/27
NCT04833894 / 2020-005841-18: Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children with Generalized Myasthenia Gravis

Recruiting
2/3
12
Europe, Canada, US, RoW
Efgartigimod IV
argenx
Generalized Myasthenia Gravis
03/27
03/27
BALLAD, NCT05267600 / 2021-003087-27: A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants with Bullous Pemphigoid

Completed
2/3
98
Europe, Japan, US, RoW
efgartigimod PH20 SC, placebo, Prednisone
argenx, argenx BV
Bullous Pemphigoid
09/24
09/24
NCT05374590 / 2021-002460-46: Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children with Generalized Myasthenia Gravis

Enrolling by invitation
2/3
12
Europe, US
Efgartigimod IV or Efgartigimod PH20 SC
argenx
Generalized Myasthenia Gravis
09/28
09/28
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
ADHERE, NCT04281472 / 2019-003076-39: A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

Completed
2
322
Europe, Japan, US, RoW
efgartigimod PH20 SC in stage B, placebo in stage B
argenx
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
05/23
05/23
ARDA, NCT05225675 / 2021-003302-50: A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults with Multifocal Motor Neuropathy

Completed
2
54
Europe, Canada, US
ARGX-117, Placebo
argenx
Multifocal Motor Neuropathy
06/24
06/24
NCT05810961: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)

Terminated
2
8
RoW
efgartigimod IV, placebo
argenx, Zai Lab Pty. Ltd.
Membranous Nephropathy
08/24
08/24
NCT05810948: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Lupus Nephritis (ZL-1103-013)

Active, not recruiting
2
73
RoW
efgartigimod IV, Placebo
argenx, Zai Lab (Shanghai) Co., Ltd.
Lupus Nephritis
07/25
09/25
ARDA+, NCT05405361 / 2021-004998-32: A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults with Multifocal Motor Neuropathy

Active, not recruiting
2
51
Europe, Canada, US
ARGX-117, Placebo
argenx, argenx BV
Multifocal Motor Neuropathy (MMN)
09/26
09/26
ADHERE+, NCT04280718 / 2019-003107-35: A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

Active, not recruiting
2
229
Europe, Japan, US, RoW
Efgartigimod PH20 SC, ARGX-113
argenx
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
03/27
03/27
NCT05817435: A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults

Completed
1
120
US
efgartigimod PH20 SC as a prefilled syringe presentation, efgartigimod PH20 SC as a vial + syringe presentation
argenx
Bioequivalence
05/23
05/23
ARGX-119-2201, NCT05670704: A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants

Completed
1
112
NA
ARGX-119, Placebo
argenx
Healthy Volunteers
08/24
08/24
NCT05927415: A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod

Completed
1
33
Europe
Efgartigimod IV
argenx
Renal Impairment
06/24
06/24
NCT06299748: A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

Recruiting
N/A
279
US
Efgartigimod, Vyvgart
argenx
Myasthenia Gravis
12/33
12/33
iMMersioN, NCT05988073: A Prospective Longitudinal Study in Adults with Multifocal Motor Neuropathy

Active, not recruiting
N/A
413
Europe, Canada, Japan, US, RoW
argenx
Multifocal Motor Neuropathy
11/25
11/25

Download Options